key: cord-0798890-8gpmu6dg
authors: Manzia, Tommaso Maria; Angelico, Roberta; Parente, Alessandro; Muiesan, Paolo; Tisone, Giuseppe
title: Global management of a common, underrated surgical task during the COVID-19 pandemic: Gallstone disease - An international survery
date: 2020-07-17
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2020.07.021
sha: 2fbd648fc9125b8dd36e500e5ca645f825388dc4
doc_id: 798890
cord_uid: 8gpmu6dg

BACKGROUND: Since the Coronavirus disease-19(COVID-19) pandemic, the healthcare systems are reallocating their medical resources, with consequent narrowed access to elective surgery for benign conditions such as gallstone disease(GD). This survey represents an overview of the current policies regarding the surgical management of patients with GD during the COVID-19 pandemic. METHODS: A Web-based survey was conducted among 36 Hepato-Prancreato-Biliary surgeons from 14 Countries. Through a 17-item questionnaire, participants were asked about the local management of patients with GD since the start of the COVID-19 pandemic. RESULTS: The majority (n = 26,72.2%) of surgeons reported an alarming decrease in the cholecystectomy rate for GD since the start of the pandemic, regardless of the Country: 19(52.7%) didn't operate any GD, 7(19.4%) reduced their surgical activity by 50–75%, 10(27.8%) by 25–50%, 1(2.8%) maintained regular activity. Currently, only patients with GD complications are operated. Thirty-two (88.9%) participants expect these changes to last for at least 3 months. In 15(41.6%) Centers, patients are currently being screened for SARS-CoV-2 infection before cholecystectomy [in 10(27.8%) Centers only in the presence of suspected infection, in 5(13.9%) routinely]. The majority of surgeons (n = 29,80.6%) have adopted a laparoscopic approach as standard surgery, 5(13.9%) perform open cholecystectomy in patients with known/suspected SARS-CoV-2 infection, and 2(5.6%) in all patients. CONCLUSION: In the ongoing COVID-19 emergency, the surgical treatment of GD is postponed, resulting in a huge number of untreated patients who could develop severe morbidity. Updated guidelines and dedicated pathways for patients with benign disease awaiting elective surgery are mandatory to prevent further aggravation of the overloaded healthcare systems.

The authors confirm that the data supporting the findings of this study are available within the article. Further details of this study are available on request from the corresponding author.

On March 11, 2020 , the World Health Organization (WHO) declared the coronavirus disease-19 (COVID-19) a public health emergency with a pandemic spread [1] . As of June 20, 2020, more than 8,525,042 confirmed cases have been reported in 216 Countries across the world [1] . Almost 20% of COVID-19 patients develop severe illness, requiring hospitalization (15%) and intensive care support (5%) [2] .

In many Countries, the healthcare systems are shifting the allocation of medical resources according to the evolution of the COVID-19 burden. To maintain the ability of hospitals to treat a large influx of potential COVID-19 patients, elective surgical activities addressing benign diseases have been suspended or limited [3] . However, elective surgery is not optional: indeed, being "presently nonurgent" does not mean being "unnecessary" [4] . Moreover, benign diseases scheduled for elective surgery may eventually lead to severe morbidity, which cannot always be harmlessly postponed.

Cholelithiasis is one of the most common medical issues in developed Countries, affecting roughly 20% of the population, and being symptomatic in one third of the cases [5] .

Laparoscopic cholecystectomy is a well-established treatment for gallstone disease (GD) [6] .

Indeed, GD is the most common gastrointestinal disorder requiring hospitalization in European Countries [6] . The annual risk of developing complications (acute pancreatitis, acute cholecystitis and cholangitis), which will cause frequent hospitalization, has been estimated to be 1-3% [5, 6] .

We conducted an international multi-center survey to evaluate the impact of the COVID-19 outbreak on the management of patients with GD scheduled for cholecystectomy, with the aim of defining possible strategies for their optimal management in the current pandemic scenario.

This study was conducted using an open, voluntary, Web-based qualitative survey designed in accordance with the "Consolidated Criteria for Reporting Qualitative Research" (COREQ) [7] and the "Checklist for Reporting Results of Internet E-Surveys" (CHERRIES) [8] . The survey was created by authors RA/TMM (MD, PhD) and distributed through a structured network involving an electronic mailing list through the academic account held by the University of Rome Tor Vergata,

Italy. An informed consent was obtained for the participation in this study, and no incentives were offered to participants. The survey involved only healthcare professionals, and did not include any patient records or confidential data, therefore no ethical approval or patient consent form were including the type of national/local health system, the volume of GDs treated at the Center, the rate of GD symptomatic patients versus those presenting complications, the waiting list times, and the elective surgical approaches to cholecystectomy. Participants were asked whether they had changed their usual management of GD patients after the WHO declaration of a viral pandemic (March 11, 2020), and which strategy they had eventually adopted based on the local context. GD was defined as the presence of gallstones causing biliary colic, and complicated GD as gallstones causing complications including cholecystitis, acute pancreatitis, bile duct obstruction and cholangitis.

Out of the 40 surgeons invited to participate in the survey, 36 responses from 14 Countries were obtained (response rate 90%), all of which were included in the analysis. The majority (n=32, 88.8%) of surgeons were based in Countries with a public health system, with 24 (66.7%) of them working in university hospitals, 7 (19.4%) in public hospitals, 3 (8.3%) in private hospitals and 2 (Table 2) .

Since the declaration of the COVID-19 pandemic, 32 (88.9%) participants stated that their hospital had dedicated areas restricted to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected patients. Two (5.6%) hospitals became exclusively dedicated to COVID-19 patients, while 2 (5.6%) are not treating COVID-19 patients as yet.

Notably, the majority (n=26, 72.2%) of surgeons reported an alarming decrease in the cholecystectomy rate for GD since the start of the pandemic, regardless of the Country: 19 (52.7%) participants affirmed that they were not currently performing any cholecystectomy, 7 (19.4%) reported a 50-75% decrease in their surgical activity, and 10 (27.8%) reduced their rate of cholecystectomy by 25-50%. Only one (2.8%) participant stated that his/her GD surgical activity was not reduced ( Table 3) .

None of the participants reported that their unit currently operated on patients with GD, unless complications had occurred. In Countries with a higher SARS-CoV-2 spread at the time of the survey -such as Italy and the UK [1] -participants stated that not even patients with complicated GD were currently being considered for surgery. The large majority of surgeons (n=32, 88.9%) said that they expected these changes to last for at least 3 more months. When asked how they would manage GD patients waiting for cholecystectomy during the COVID-19 outbreak, 21 (58.3%) participants said that they would maintain the service only for patients with complicated GD, with 

Since the COVID-19 outbreak reached pandemic levels, recommendations for the fair allocation of resources should be based on the following principles: maximizing the benefits of medical interventions, protecting and preserving the healthcare workforce, paying attention not to allocate resources only on a first-come/first-served basis, being responsive to evidence, and applying the same principles to both COVID-19 and non-COVID-19 patients [9] .

International surgical societies recommend to avoid elective surgical procedures, including cholecystectomy, in order to ration the use of the medical resources (ICU beds, ventilators, and personal protective equipment) and the healthcare professionals needed to face the COVID-19 pandemic [3] . Conversely, emergency and oncological surgeries should be continued [3] .

Our survey depicts a wide adherence to this rule. Cholecystectomy is, in fact, reserved only for patients with acute GD-related complications. Of these, 70% of cases are treated surgically, while 30% are managed by medical treatment alone. Although these results could be expected, surprisingly, in terms of cancellation of GD surgery schedules, responses did not differ among participants from Countries at different stages of COVID-19 spread. This results in a large number of patients affected by uncomplicated but symptomatic gallstones -50% of whom suffering from frequent colic -and by the uncertainty about when definitive surgery could be performed. This scenario may conceivably increase the risk of developing gallstone-related complications, such as acute cholecystitis, cholangitis and acute pancreatitis, which would inevitably require hospitalization, and eventually urgent care [5, 6] . Gallstone-related acute pancreatitis -which has an annual incidence ranging from 15 to 40/100,000 across different Countries [10, 11] -could potentially be a life-threatening complication, requiring urgent endoscopic or surgical intervention.

Additionally, a more advanced disease at the time of surgery may result in increasingly morbid operations, which are associated with prolonged hospital stay and higher costs [4] . Since the global healthcare community has never faced a dramatic scenario such as the COVID-19 pandemic, it is difficult to forecast the effects of untreated GD and the development of its related complications during and after COVID-19. Recent US reports [12, 13] show that the visits to the Emergency Department declined up to 50% during the early period of the COVID-19 pandemic, due to the patients' fear of contracting the SARS-CoV-2 infection. This led to an increase in the mortality and morbidity rates for life-treating diseases, such as cardiovascular events [14] . However, so far there are no specific data available on GD-related complications [12] . Based on pre-pandemic data, assuming that the current crisis could last for 10 weeks [15] , over 23,400 cholecystectomies in Italy and 18,200 in UK would be delayed, since almost all GD surgeries in these Countries have been suspended [16] .

This huge number of untreated GDs suggests that, in the current COVID-19 pandemic, the surgeons' responsibility should not only be to care for emergency or oncological cases, but also to prevent patients with benign, uncomplicated diseases from developing complications, further aggravating the pressure on the health systems. Since this survey shows that 90% of hospitals are treating COVID-19 patients, dedicated COVID-19-free pathways and precautions should be preserved for all other cases [17] . Most surgeons agree on the need to proceed with surgery only in GD patients with complications. For uncomplicated symptomatic patients, who are treatable by laparoscopic cholecystectomy -which usually doesn't require a post-operative ICU stay -a possible alternative might be the wider use of ambulatory surgery. The current survey shows that only 39% of Centers routinely perform cholecystectomy in a day case ambulatory setting. It is well-known that an ambulatory regimen is both feasible and costeffective [18, 19] , therefore this strategy could be a good option in the current pandemic to limit any further hospital overload. However, the high turnover of patients and healthcare providers in ambulatory care services, despite reducing hospitalization, could be a further potential source of viral infection among the medical staff in the course of their daily activity. In this regard, it might be safer to ask patients to self-quarantine for 14 days prior to surgery, as well as to obtain a PCR negative test before the operation. This, combined with a wider use of personal protective equipment (PPE) and COVID-19-free dedicated surgical pathways, could improve the number of ambulatory admissions.

Alternatively, according to the initial experience of China and Italy [17] , in hospitals lacking day case surgical services, patients with GD awaiting elective cholecystectomy should be transferred to other COVID-19-free hospitals.

Since the start of the COVID-19 pandemic, concerns have been raised regarding the safety of smoke evacuation during laparoscopic surgery, as the virus could potentially spread during laparoscopy [17] . However, open cholecystectomy might lead to an increased risk of post-operative infection, and therefore a prolonged hospitalization, whereas laparoscopic cholecystectomy can be safely performed as a day case surgical procedure, thus reducing the hospitalization time [5, 6] . Recently, even in confirmed or suspected COVID-19 cases, some authors suggest to use safe and reliable filtering and evacuation systems for pneumoperitoneum gases, which could decrease the chances of viral spreading, enabling the safe use of the laparoscopic approach [21] . In our opinion, protecting the healthcare teams with a safety-first approach is mandatory; thus, with the PPE and adequate smoke evacuation systems (filters, careful deflating, traps) [21] , laparoscopic cholecystectomy for GD could be safely performed. This would lead to a reduced hospitalization time, which is extremely helpful for some categories of patients affected by GD (i.e. high BMI and the elderly). In addition, it could potentially spare medical personnel and resources. However, the circulation of information on the COVID-19 transmission is continuously evolving, and it is likely that further data will come out in the next future to provide evidence-based recommendations for the surgical practice.

The results of this survey are limited by the small number of participants for each Country, the heterogeneity of the surgical Centers and the rapidly changing scenario of the COVID-19 pandemic. Furthermore, since the survey was conducted during the initial four weeks of the pandemic, it lacks the data regarding the outcome of GD complications and their treatment after the COVID-19 outbreak. To address this issue, further studies are needed.

To the best of our knowledge, this is the first study to show the potential impact of the COVID-19 pandemic on a benign disease requiring elective surgery, such as symptomatic GD. In the ongoing COVID-19 emergency, there is a substantial risk that many other benign diseases -which may develop complications if left without surgical treatment until the end of the pandemic -could have unexpected consequences for the healthcare systems. Therefore, as for life-saving procedures, it is of paramount importance to generate updated guidelines for the fair management of patients with benign disease in need of elective surgery during the pandemic, or immediately thereafter.

Not commissioned, externally peer reviewed. 

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

American College of Surgeons. COVID-19 guidelines

The Consequences of Delaying Elective Surgery: Surgical Perspective

European Association for the Study of the Liver (EASL)

Evidence-based clinical practice guidelines for cholelithiasis 2016

Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups

Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)

Fair Allocation of Scarce Medical Resources in the Time of Covid-19

The incidence and aetiology of acute pancreatitis across Europe

The epidemiology of pancreatitis and pancreatic cancer

Impact of the COVID-19 Pandemic on Emergency Department Visits -United States

Where are all the patients? Addressing Covid-19 fear to encourage sick patients to seek emergency care

Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China

Ten weeks to crash the Curve

Annual surgical procedures in each Country. Organization for the economic co-operation and development

Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China and Italy

Where Is the Value in Ambulatory Versus Inpatient Surgery? Ann Surg

Feasibility and cost effectiveness of ambulatory laparoscopic cholecystectomy. A retrospective cohort study

Updated Intercollegiate General Surgery Guidance on COVID-19

A Low Cost, Safe and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients

• Since the start of the COVID-19 pandemic, elective surgeries for benign diseases have been postponed, in order to preserve healthcare resources.• A global survey on the surgical management of patients with gallstone disease during the COVID-19 pandemic showed that patients with cholelithiasis -for whom surgery is indicated -are not operated, unless the disease is complicated.• The block of elective surgery during the pandemic will results in a large number of patients affected by gallstone disease, who could develop severe morbidity, requiring hospitalization and urgent care.• Dedicated COVID-19-free pathways for patients with benign disease waiting for elective surgery are needed to prevent any further aggravation of the already overloaded healthcare systems.

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.All the authors declare that there are no conflict of interest regarding the publication of this manuscript.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.None of the authors received any funding, direct or indirect, related to the achievement of this work from any organizations.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.As the study is a qualitative survey among health care professionals without any involvement on patient data, no approval was required.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.No patients were involved in the study. An informed consent was obtained for the participation in this study from the surgeons survived.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.TMM and RA: study design and conception, acquisition of data, formal analysis and interpretation of data, drafting the article, final approval of the version to be submitted. AP: data curation and analysis, reviewed the manuscript. PM and GT: revising it critically for important intellectual content and final approval of the manuscript.

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.1. Name of the registry: Research Registry 2. Unique Identifying number or registration ID: researchregistry55493. Hyperlink to your specific registration (must be publicly accessible and will be checked):https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5ea81b67c7420a0015c20023/

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Roberta Angelico Tommaso Maria Manzia